title: The Role of Fludrocortisone in Cognition and Mood in Patients with Primary Adrenal Insufficiency (Addison's Disease).
abstract: Primary adrenal insufficiency (AI) requires hormone replacement therapy with fludrocortisone and hydrocortisone stimulating glucocorticoid (GR) and mineralocorticoid receptors (MR). Evidence from animal and human studies shows that MR function is crucial for cognitive function and mood. Regarding patients with AI, very little is known about the role of MR in cognitive function and mood.
  
  
  
  A repeated-measures within-subject design was used to determine whether cognitive function and mood are related to MR occupation in patients with AI. Intraindividually, patients were examined twice, with 1 week between testing days: once with fludrocortisone (high MR occupation) and once without fludrocortisone (low MR occupation). All patients kept their stable regimen of hydrocortisone. The assessment of cognitive function included executive function, attention, and verbal, visuospatial and working memory. Additionally, mood and blood pressure were measured.
  
  
  
  Verbal memory improved significantly during high MR occupation (after fludrocortisone intake) compared to low MR occupation [without fludrocortisone, t(29) = -2.1, p = 0.046]. There were trend level differences in the Number-Combination test [t(29) = -1.9, p = 0.074] and in the Stroop interference task [t(29) = -1.9, p = 0.068]. No significant differences in visuospatial and working memory were found. Furthermore, the current mood state was better during high MR occupation compared to low MR occupation [t(29) = -2.4, p = 0.023] as was diastolic blood pressure [F(2, 29) = 3.6, p = 0.07].
  
  
  
  Cognitive function and mood in patients with AI depend in part on MR occupation. Because the medium effect size indicates a potential clinical significance, further studies should systematically examine which dosages of fludrocortisone are associated with optimal cognitive function and mood in AI patients.
authors.affiliation: Department of Psychiatry and Psychotherapy, Charitx00E9; University Medical Center, Campus Benjamin Franklin, Berlin, Germany.
authors.forename: Katharina
authors.initials: K
authors.lastname: Schultebraucks
authors.forename: Katja
authors.initials: K
authors.lastname: Wingenfeld
authors.forename: Christian
authors.initials: C
authors.lastname: Otte
authors.forename: Marcus
authors.initials: M
authors.lastname: Quinkler
mesh_terms: D000224:Addison Disease / Q000150:complications* / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000378:metabolism* / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D005438:Fludrocortisone / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000188:drug therapy / Q000209:etiology*; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales
chemical_list: D000893:Anti-Inflammatory Agents; D005438:Fludrocortisone